Contents

24 June 2020
Vol 12, Issue 549

About The Cover

Cover image expansion

ONLINE COVER Immune Pas de Deux. This illustration depicts the interactions between a T cell (yellow at the center) and tumor cells (live cells in brown and dead cells in blue) in the context of combination therapy with an immune checkpoint inhibitor (purple) and CD28-based costimulatory bispecific antibodies (green). CD28 bispecific antibodies cross-link tumor cells with T cells, while the immune checkpoint inhibitors prevent inactivation of the T cells, facilitating tumor cell killing. As demonstrated by Waite et al., this immunotherapeutic combination is safe and effective in multiple mouse models of cancer, including those resistant to immune checkpoint inhibition alone. [CREDIT: HRATCH ARBACH]